Lumenis Announces Regulatory Approval for the Lumenis One™ in China and Sale of Over 500 IPL® Quantum™ Systems in Asia Pacific

Yokneam, Israel, June 20, 2005 – Lumenis^® Ltd. (LUME.PK), a global developer, manufacturer and seller of laser and light-based devices for medical, aesthetic, ophthalmic, dental and veterinary applications, announced today that it has received regulatory approval for the Lumenis One from the State Food and Drug Administration (SFDA) of China. Lumenis also announced today that it has sold more than 500 IPL Quantum systems in the Asia Pacific region, which consists of all of Asia outside of Japan.

Avner Raz, President and Chief Executive Officer, stated, “Receiving approval for our Lumenis One system from the SFDA in China represents a major milestone. It enables us to market the system without restriction and to be purchased more easily by government hospitals. Another significant milestone was the sale of more than 500 IPL Quantum systems in Asia Pacific since receiving SFDA approval for the Quantum in 2001. This is a clear demonstration of the high level of satisfaction our customers have with our products.”

Lumenis One represents the fourth generation of IPL technology and reinforces Lumenis’ place at the forefront of innovation in the aesthetic market. Optimizing and building upon a firm foundation, Lumenis One unites three gold standard technologies on one multi-technology and multi-application platform: Intense Pulsed Light for skin photorejuvenation and treating vascular and pigmented lesions, the LightSheer® diode laser for hair removal and the Multi-Spot™ Nd:YAG for treating leg veins and deeper vascular lesions. The system’s key features include Optimal Pulse Technology (OPT™), numerous presets, easy custom settings and an intuitive touch-screen software interface. These enable Lumenis One to provide increased patient comfort, faster treatments and easily tracked patient information.

The IPL Quantum is Lumenis’ mid-range multi-application aesthetic system and is used to treat a wide variety of conditions including skin treatments using photorejuvenation, permanent hair reduction and deep leg veins. Its superior clinical results, ease of use and upgradeability have made Lumenis’ IPL Quantum the system of choice in more than 2,200 aesthetic practices worldwide.

Lumenis is a global developer, manufacturer and seller of laser and light-based devices for medical, aesthetic, ophthalmic, dental and veterinary applications. The Company offers a wide range of products along with extensive product support systems including training, education and service. Lumenis invests heavily in research and development to maintain and enhance its leading industry position. The Company holds numerous patents worldwide on its technologies. For more information about Lumenis and its products, log onto www.lumenis.com.


Contact:

Lauri Hanover, CFO
1-866-232-6803
+972-4-959-9122

The statements in this press release that are not historical facts are forward-looking statements that are subject to risks and uncertainties. The Company's actual results could differ materially from those anticipated in the forward looking statements based on a variety of factors, including, among others: uncertainties with respect to market acceptance of the Company's products, the implementation and outcome of its Turnaround Plan, obtaining regulatory approvals for new products or for the sale of existing products in new markets and enforcement of intellectual property rights; risks associated with competition and competitive pricing pressures, economic conditions generally, the Company's international operations and the Company's ability to integrate its operations with those of acquired businesses; the outcome of the Securities and Exchange Commission investigation and several securities class action lawsuits to which the Company is subject and the outcome of the investigation conducted by the Audit Committee; uncertainties relating to the Company’s continuing liquidity; and other risks detailed from time to time in the reports filed by Lumenis with the SEC, including its annual report on Form 10-K and quarterly reports on Form 10-Q.